Humanin is a small peptide originally identified in the human brain, specifically within the mitochondrial genome. It consists of 24 amino acids and is known for its potential protective effects against various cellular stressors. Humanin can be synthesized chemically or expressed recombinantly in laboratory settings. Its structure allows it to interact with multiple cellular pathways, making it a subject of interest in anti-aging and longevity research. Researchers have investigated Humanin primarily for its neuroprotective and cytoprotective properties. Studies have shown that it may help protect neurons from apoptosis induced by Alzheimer's disease-related toxins. Additionally, Humanin has been observed to have beneficial effects on metabolic regulation, cardiovascular health, and insulin sensitivity. The mechanism of action of Humanin involves interaction with several receptors and signaling pathways. It is known to bind to the formyl peptide receptor-like 1 (FPRL1) and the ciliary neurotrophic factor receptor (CNTFR), among others, leading to activation of survival pathways such as the STAT3 and ERK1/2 pathways. These interactions help mediate its protective effects against cellular stress. Pharmacokinetic studies of Humanin are limited, but researchers have noted that it has a relatively short half-life, which may vary depending on the route of administration. Its stability and bioavailability are subjects of ongoing research, with some studies suggesting rapid degradation in the bloodstream. Current research on Humanin is focused on understanding its full range of biological activities and potential therapeutic applications. It is not approved as a medicinal product by major regulatory agencies, and its use is primarily confined to research settings. Regulatory standing varies by country, with Humanin often categorized as a research chemical.